Abstract. Dissected specimens of colorectal cancer (cRc) have been intensively studied using molecular sketches (gene signatures) to obtain a set of discriminator gene signatures for accurate prognosis prediction in individual patients. The discriminators obtained so far are not universally applicable, as the gene sets reflect the method and site of the study. In this study, we show that dissected stage II and III cRc samples are significantly heterogeneous in molecular sketches, and are not appropriate sources for discriminator extraction unless handled individually. To search for an accurate discriminator gene set for prediction of metastases, we need to start with less heterogeneous stage II cRc. We examined 198 (92 stage II and 106 stage III) cRc dissected samples for the predictability of discriminator gene signatures by analyzing stage II cRc alone, stage III alone, or in combination. The best predictive power of discriminator genes was obtained only when these genes were extracted and validated with stage II cRc samples. An accurate discriminator gene set for the prediction of cRc metastases can be obtained by focusing on stage II cRc samples.
Introduction
colorectal cancer (cRc) is the second most common malignancy in developed countries (1,2). colon carcinogenesis is a multi-step process involving progressive changes in genomes and regulatory pathways in colonic epithelial cell proliferation, differentiation and survival, followed by extravasation into lymphatic or blood flow systems. It is categorized into stages I, II, III and IV, depending on the extent of tumor penetration into the intestinal wall, the number of locoregional lymph nodes containing metastases, and distal organ metastases. According to the guidelines of the American Society of clinical Oncology (AScO) and National comprehensive cancer Network (NccN), it is recommended that, in most cases, stage II and III cRc tumors be surgically removed. Additional chemotherapy is also recommended for the prevention of metastases for all stage III cRc patients, as well as for some patients with highgrade stage II cRc. However, no adjuvant chemotherapy is recommended on many low-grade stage II cRc patients (3-5). However, some of the stage III patients do not develop recurrence, and some stage II patients do develop recurrence. Therefore, whether or not adjuvant chemotherapy is used after surgery can affect patient survival and quality of life. The cost of medical care is also debatable.
The ongoing individual prediction of cRc prognosis relies mostly upon the clinicopathological observation of the patient. However, the factors available so far, including the depth of tumor invasion (T-stage), and lymph nodal (N-stage) and lymphovascular invasion, are not fully discriminative for correctly predicting the prognosis. Microarray technology with genome-wide analyses of gene expression profiles (gene signatures) of the dissected tumor specimen can help to discover a set of discriminator genes for accurate prognosis prediction in individual patients. Some of these markers may be used to elucidate the genes that are active (or inactive) in metastatic tissues. Remarkable success has been demonstrated in breast cancer (6) (7) (8) . Similar attempts have been made in cRc (9-21), but the gene sets differ between different laboratories (22) and the predictive power of these discriminators is not as high as expected. It has been argued that these problems may have arisen from the differences in patient treatment, such as adjuvant chemotherapy application, limited number of samples (17, 23) , differences between work platforms, handling of samples, and statistical methods used. In addition, highdimensional prediction may yield many models with the same fit (10). We have been working with nearly 700 CRC samples collected in a consortium under a unified protocol to obtain a reliable set of discriminators for metastasis prediction, but so far without success. The difficulty may have stemmed from the hitherto unidentified complexity or heterogeneity of molecular sketches of cRc. We therefore attempted to reduce the complexity of the samples by focusing on stage II, rather than working with a mixture of stages II and III cRc cases. In this study, we report the results of analyses along this line, and show that focusing on stage II cRc allowed us to obtain a better discriminator gene set for the personalized prognosis of metastasis.
Materials and methods
Patients and clinical materials. In over 5 years, we collected 1978 fresh cRc samples. Data of these patients were added to the registry between 2003 and 2005 (Fig. 1A) . All the patients were registered without omission and their prognostic data were up-dated once a year. Post-operative surveillance included clinical evaluation, laboratory tests (including serum carcinoembryonic antigen assay), abdominal cT/US, chest radiography, and colonoscopy in all patients. None of these patients had received chemotherapy.
The study protocol was approved by the Human Ethics Review committee of Osaka University graduate School of Medicine, and a signed consent form was obtained from each subject.
RNA preparation, labeling, hybridization and data management.
The dissected samples were handled for RNA preparation and analysis at one laboratory station using a standard protocol. Tumor samples were collected within 30 min from the time of resection. They were immediately cut into 5-mm cubes, and after the addition of an RNAase inhibitor, they were stored at -85˚C until RNA extraction. For RNA preparation, samples were dissected from the frozen tissues and homogenized by hand. Total RNA was purified with a TRIzol reagent (Invitrogen, San Diego, cA, USA) using the protocol supplied by the manufacturer. The RNA integrity was assessed with an Agilent 2100 bioanalyzer and RNA 6000 Labchip kits (yokokawa Analytical Systems, Tokyo, Japan). Only high-quality RNA with intact 18S and 28S ribosomal RNAs was used for subsequent analysis. Reference colorectal RNA was prepared by combining 40 RNA preparations from normal colorectal mucosa.
The RNA samples were amplified with T7 RNA polymerase using an Amino Allyl MessageAmp™ aRNA kit (Ambion, Austin, TX, USA) according to the manufacturer's instructions, and the quality of each Amino Allyl-aRNA sample was checked with the Agilent 2100 bioanalyzer. control and experimental aRNA samples (5 µg) were labeled with cy3 and cy5, respectively, and were mixed and hybridized on an oligonucleotide microarray covering 30,000 human probes (Acegene Human 30k; Hitachi Software Engineering co., yokohama, Japan). The experimental protocol is described in detail online (http:// www.dna-chip.co.jp/thesis/AcegeneProtocol.pdf). The microarrays were scanned using ScanArray 4000 (gSI Lumonics, billerica, MA, USA). The signal values were calculated by DNASISArray software (Hitachi Software Inc., Tokyo). Following background subtraction, data with low signal intensities were excluded from subsequent analysis. In each sample, the cy5/cy3 ratio values were log-transformed and global equalization was applied. genes with missing values in >10% of samples were excluded from further analysis. Analyses of the expression data. For the gene signature assay, samples (in this particular experiment n=129) were divided into two groups, one for the training set and another for the validation (test) set. The ratio of recurrence/recurrence-free cases was selected to be equal in the training set and validation set. calculations within the training set were carried out repeatedly by changing the number of samples (from 10 to 60) in the training set (training set size). We performed 600 random tests in each training set size. Improvement in the mean accuracy was observed with increasing training set size. In this particular experimental system, 600 random tests with a training set size of 50 samples yielded 73% mean accuracy and 6.3% standard deviation, allowing us to adopt a training set size of 50 samples for further analyses. The discriminator genes were selected using the signal-to-noise ratio (SNR) as computed for each gene in the training set. calculation of the mean accuracy, positive predictive value (PPV, i.e., positive recurrence), and negative predictive value (NPV, i.e., negative relapse for each stage) was carried out based on 100x6 gene selections and validations conducted for each training set size. Missing values were imputed by a simple k-nearest neighbor algorithm (24) and the value of k was set to 5, as described previously (25).
For each gene i, the SNR was defined as SNR (i) = ⎪µ
i denote the means and standard deviations of two classes, respectively. The nearest mean classifier was employed in a previous study (7), and confirmed to be effective for outcome prediction despite its simplicity.
Results

Patients and clinicopathological analyses for personalized predictors of metastasis.
To obtain as many patient samples as possible while keeping a constant sample quality, the vital requirements for this study, we set up a neo-paradigm of cancer treatment (NcT) consortium in the kansai area in Japan. This collaborative effort allowed us to collect cRc samples under a unified system of diagnosis, categorization and description of clinicopathological findings. Among the 1978 samples registered (Fig. 1A) , we obtained 693 cRc samples, 331 stage II and 259 stage III cases, free of recurrence, along with 40 stage II and 63 stage III cases that developed distant metastases (Table I) . We attempted to sort the 693 cases into good or poor prognosis based solely on clinicopathological findings, such as depth of tumor, lymphatic invasion, and vascular invasion. Univariate analysis of stage II and III cRc patients suggested that recurrence could be correlated with certain factors, such as lymphatic invasion or vascular invasion. However, when we performed multivariate cox proportional hazards regression analysis, no independent single predictor was found for recurrence in stage II cRc, while depth of tumor and lymphatic invasion were independent predictors for stage III cRc patients. (verification) . Discriminator genes are obtained by comparing gene signatures between non-metastasis samples and metastasis samples in a training set. They are then tested (validated) using an independent set of samples for the test. In the single split validation (upper blocks), the training set and test (validation) set are the same. In MRV (lower blocks), as described by barrier et al (10), the extracted discriminators are tested using a new and independent set of samples. We used the MRV for our study. We used 129 samples (70 non-metastasis, 59 metastasis) for discriminator extraction, and 69 samples for the test.
Discriminator extraction using expression profiles (gene signatures) and its verification. We then took 129 dissected specimens (70 patients with no metastasis and 59 with metastasis; Table IIA) from the 693 samples and analyzed the gene signatures. RNA extraction, microarray analyses and data management were carried out as described in Materials and methods. Expression profiles were then compared between the metastatic (recurrence) and non-metastatic samples to extract discriminator genes using a multiple random trainingtest strategy (MRV) system, as described by barrier et al (10) (Fig. 1b) . The resulting discriminators were used as those of the training set samples. We then took another independent set of 69 samples shown in Table IIB for validation (verification) of the discriminators. The validation with a new, independent set of samples guarantees the results to be free from overfitting (Fig. 1B) .
To test the quality of the discriminators, we extracted them from different combinations of stage II and stage III mixtures. The sources for this experiment are shown in Table II . Samples in each stage were randomly selected, admixed at a ratio of 100/0, 80/20, 60/40, 40/60, 20/80 and 0/100, and each of them was used as a training set. Six different discriminator sets were thus obtained, and were subjected to validation using two independent test sets (consisting of stage II alone or stage III alone) constructed from samples in Table IIA . The results are shown in Fig. 2A and b . The proportion of stage II and III samples in the training set greatly affected the accuracy of the resulting discriminators: The higher the proportion of stage II samples in the training set, the higher the accuracy, when evaluated with stage II validation samples ( Fig. 2A) . However, when we used the same set of discriminators and evaluated with stage III validation samples, we obtained a similar trend, but the highest mean accuracy was not high (Fig. 2b) . The favorable result obtained with the stage II combination was not due to the matching of stages between training and validation sets, as seen in the stage III combination. The best performance was obtained with the combination of stage II training samples and stage II validation samples. For example, in an independent, but similar experiment in which both the training and test were performed with stage II samples (Table III) , the results showed 18/23 (78.3%) non-recurrences and 6/8 (75%) recurrences; the prediction accuracy being (18+6)/(23+8) (77.4%), with a PPV of 6/(5+6) (54.5%) and a NPV of 18/(18+2) (90.0%). In contrast, when training and tests were performed with stage III samples, the correct prediction was 10/(10+18) (35.7%) non-recurrences and 8/(8+2) (80%) recurrences, and the prediction accuracy was (10+8)/(28+10) (47.4%), with a PPV of 8/(18+8) (30.8%) and a NPV of 10/ (10+2) (83.3%). These data strongly suggest that stage III samples are more heterogeneous than stage II samples.
The appropriate number of informative discriminator genes with the largest value was identified by changing their number (from 5 to 150) in each training-validation. We selected 30 top-ranking genes with the largest values as discriminators for prediction (Fig. 2c) . When the number is small, there is underpowered predictability, and when large, there is a complication.
Difference in clusters of gene signature between stage II and stage III CRC.
To obtain further evidence for the heterogeneity in stage III samples, we subjected the gene signatures of the 129 CRC samples to cluster analyses. Profiles of samples of non-metastatic stage II, metastatic stage II, non-metastatic stage III, and metastatic stage III were compared using ANOVA analysis. All the data were quantile normalized after assembly, and data with genes having >6 missing samples were eliminated to avoid possible bias resulting from microarray processing. The results are shown in Fig. 3 . All non-metastatic stage II samples were located in cluster 1, whereas nonmetastatic stage III samples were almost evenly distributed within clusters 1 and 2. Four and six metastasis samples from stage II and III, respectively, were located in cluster 1, while 48 metastasis samples from stage II and stage III were in cluster 2. These results showed that the stage III samples were more heterogeneous than the stage II samples (p-value <E-7). The metastatic samples from stage II and stage III were similar, if not identical, and were different from the nonmetastatic stage II samples.
Genes selected by MRV. We selected 100x30 discriminator genes (3,000 genes) by 100 MRV in the training set that included only tumors of the same stage. We selected 491 genes from the stage II training set, wherein the number of genes selected 50 to 100 times was 11. However, 1,161 genes were selected from the stage III training set, and only one gene was selected in the window of 50 to 100 MRV, in conformity with the idea that stage III is more heterogeneous than stage II. Table IV shows the 30 discriminator genes for prognosis from stage II samples repeatedly selected by MRV. Table V .
Discussion
Although the current staging system of cRc based on TNM classification is useful for correlating groups of patients with different recurrence rates, it cannot be directly used for the personalized prediction of recurrence for stage II or III patients. Some of these patients will be cured, whereas others will develop recurrence, even though they had similar clinicopathological findings and were operated and treated similarly in after-care. However, another problem is that a significant fraction of the patients receive unnecessary chemotherapy. Personalized prediction of recurrence is awaited to avoid under-treatment or over-treatment, and therefore, the demand is high for expression signatures for their possible contribution on this issue. A set of discriminator genes to differentiate good prognosis and poor prognosis must be obtained. This is not just collecting one or a few metastasis-related genes for understanding the cause and consequence of functional change in a gene that is related to metastasis. Discriminators are extracted by a different approach. As noted in the Introduction however, discriminators obtained from several laboratories are not the same, and their performance has not been convincing. We have been working along the same line, and noticed also the lack of robustness with the cRc discriminator set from different studies. This could be due, in part, to the difference in the platform used or sample handling, or to the small sample numbers. However, cRc might be more heterogeneous than expected. This would cause difficulty in defining the category of 'good prognosis cRc', or 'poor prognosis cRc' by assuming that each of them represents a relatively uniform single entity. cRc has been reported to be heterogeneous clinicopathologically, but attempts for sub-categorization have not been successful. Weiser et al found by nomogram studies great heterogeneity within cRc (26), especially the stage III cohort, and possible variability in the probability of recurrence. (26) . Although the application is limited at this moment, we believe that focusing on stage II cRc is clinically important for the personalized care and management of the cRc patients.
The discriminator gene set is not complete even for stage II cRc (prediction accuracy 77.4%). Nevertheless, the following genes may be of some interest: Pregnancy-specific β-1-glycoprotein 3 (PSg3), which is a member of the carcinoembryonic antigen (cEA) gene family; TP73L (p63), a member of the p53 family related to the negative regulation of the cell cycle and apoptosis; DLEC1, a tumor suppressor gene identified in lung, esophageal and renal cancers; PLcE1, a regulator of small gTPases of the Ras superfamily; and Muc4, a regulator of p27, that is a cyclin-dependent kinase inhibitor involved in the control of g1 and S phases of the cell cycle, linked to poor prognosis in many cancers. Other genes include TNFRSF6b, HSPA1b and IFI6, which guard against apoptosis.
How did the heterogeneity of cRc, especially that of stage III cRc, evolve? To answer this question we need to subdivide stage II and III CRC using gene expression profiles. We also need to know whether or not metastatic cRc is similar, or very heterogeneous, as suggested by the profiles shown in Fig. 3 profiles, and also indirectly by Jorissen et al (14) . In breast cancer, gene signature prediction of recurrence (7, 8) has been approved by the Food and Drug Administration. The products are currently available (6), and have been recommended for use in the AScO and NccN guidelines. The accuracy of predicting prognosis in cRc cases is not as high as that in breast cancer cases, even when its application is limited to stage II cRc cases. Further studies to accurately categorize CRC by combining clinicopathological findings and molecular analyses will enable more strategic personalized prediction, and will allow for the appropriate validation and clinical application of these findings (22).
In summary, our diagnostic system using the gene signature of stage II cRc, however limited in capability, should be useful for the prediction of prognosis of individual patients after curative surgery. The expression profiling data and supplemental information are available at (http://www.ncbi. nlm.nih.gov/geo/query/acc.cgi?acc=gSE12032).
